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ABSTRACT
Glis3 is a member of the Kru ¨ppel-like family of tran-
scription factors and is highly expressed in islet b
cells. Mutations in GLIS3 cause the syndrome of
neonatal diabetes and congenital hypothyroidism
(NDH). Our aim was to examine the role of Glis3
in b cells, specifically with regard to regulation of
insulin gene transcription. We demonstrate that
insulin 2 (Ins2) mRNA expression in rat insulinoma
832/13 cells is markedly increased by wild-type
Glis3 overexpression, but not by the NDH1 mutant.
Furthermore, expression of both Ins1 and Ins2
mRNA is downregulated when Glis3 is knocked
down by siRNA. Glis3 binds to the Ins2 promoter
in the cell, detected by chromatin immunoprecipi-
tation. Deletion analysis of Ins2 promoter identifies
a sequence (5’-GTCCCCTGCTGTGAA-3’) from  255
to  241 as the Glis3 response element and binding
occur specifically via the Glis3 zinc finger region
as revealed by mobility shift assays. Moreover,
Glis3 physically and functionally interacts with
Pdx1, MafA and NeuroD1 to modulate Ins2 promoter
activity. Glis3 also may indirectly affect insulin
promoter activity through upregulation of MafA
and downregulation of Nkx6-1. This study uncovers
a role of Glis3 for regulation of insulin gene expres-
sion and expands our understanding of its role in
the b cell.
INTRODUCTION
GLI and GLI-similar (Glis) transcription factors are
two closely related subfamilies of Kru ¨ ppel-like zinc
ﬁnger (ZF) proteins (1–3). These factors contain ﬁve zinc
ﬁngers in tandem for DNA binding. The Glis subfamily
is comprised of three members Glis1 to 3. Glis proteins
contain both repressor and activator domains, suggesting
that they may function as positive and negative regulators
of gene transcription. During embryonic development,
Glis proteins are expressed in a spatially and temporally
speciﬁc manner, suggesting that they may play key roles
in normal organogenesis. Glis1 is involved in the aber-
rant diﬀerentiation observed in psoriatic epidermis (1).
Glis2 is highly expressed in the kidney, and loss of Glis2
causes nephronophthisis in humans and mice through
increased apoptosis and ﬁbrosis (4,5). Glis2 has also
been shown to be involved in the regulation of neuronal
diﬀerentiation (2). Glis3 is highly expressed in the
metanephric mesenchyme during embryonic development
and in the uterus, pancreas and kidney of adult mice (3). It
was also shown to bind to the promoter of ﬁbroblast
growth factor 18 (FGF18) and promote osteoblast diﬀer-
entiation (6).
In vitro assays indicate that all ﬁve ZF motifs appear
essential for the binding of Glis3 to DNA, and the fourth
ZF is also involved in the nuclear localization of Glis3
(3,7). The C-terminal region of the protein contains a
strong transactivation domain, and its deletion abolishes
transcriptional activity. A recent report identiﬁed a
consensus binding site for Glis3 to be (G/C)TGGGGGG
T(A/C) using a DNA-binding site selection strategy that
combines PCR and electrophoretic mobility shift assays
(EMSA) (7). However, this sequence was isolated by
in vitro experiments and has not been identiﬁed in any
endogenous Glis3 responsive promoters thus far.
Linkage analysis revealed that mutations in GLIS3 are
responsible for the syndrome of neonatal diabetes and
congenital hypothyroidism (NDH) (8). Glis3 mRNA is
present in human and mouse pancreas from early devel-
opmental stages through adulthood, with higher expres-
sion in b cells than in other pancreatic islet or exocrine
cells (8). However, the functional role of Glis3 in b cells
has not been explored. Pancreatic islet development, b-cell
maintenance and insulin gene transcription are dependent
on multiple islet-enriched transcription factors, including
Pdx1 (9–11), MafA (12–14), Pax6 (15,16) and BETA
2/NeuroD1 (17,18). Rat insulin promoter analyses have
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regions, C2 (Pax6), A3 (Pdx1), C1 (MafA) and E1
(BETA2/NeuroD1) (19,20). Other factors known to be
involved in insulin gene transcription include Nkx6-1
and Pax4, both of which may have a repressive role.
Study of these factors has provided insights into the
machinery of insulin gene regulation and the pathogenesis
of diabetes. As Glis3 is highly expressed in pancreatic
islets and mutations in GLIS3 cause neonatal diabetes
in humans (8,21), we hypothesized that this factor may
regulate insulin gene expression. In this study, we found
that Glis3 binds to a cis-acting element (Glis3 response
element, Glis3RE) in the rat insulin 2 promoter (RIP)
and stimulates its transcription activity. Furthermore,
Glis3 interacts with b-cell-speciﬁc transcription factors—
Pdx1, MafA and NeuroD1—and can interact with these in
a synergistic manner to increase insulin promoter activity.
In addition, Glis3 also regulates the expression of
a number of b cell transcription factors, such as MafA,
Nkx6-1 and Pax6. These ﬁndings constitute the ﬁrst
evidence that Glis3 regulates insulin gene expression in
pancreatic b cells.
MATERIALS AND METHODS
DNA constructs
Using the known coding sequence of mouse Glis3 gene
(Genbank accession number NM_175459), we constructed
Glis3 cDNA and a Glis3 mutant cDNA (Glis3-NDH1)
that corresponds to the sequence in a family with neonatal
diabetes and congenital hypothyroidism (NDH1) syn-
drome (8) by PCR mutagenesis, inserting a C nucleotide
at 2930 of wild-type Glis3. The mutant Glis3-NDH1 pro-
tein terminates prematurely at aa 844 compared to the
full-length protein of 935 aa.
The Glis3 cDNAs as well as control yellow ﬂuorescent
protein (YFP) were ampliﬁed by using PCR and cloned
into the retroviral vector pSRQT (22). Additional con-
structs were generated for transient transfection by using
a human elongation factor 1a (BOS) promoter-driven
expression vector pBOS-MCS (23). SRa-Secreted
Alkaline Phosphate (SEAP) construct was kindly pro-
vided by Dr David Spencer (Department of Immunology,
Baylor College of Medicine). The coding sequences of
mouse Glis3, Glis3-NDH1, MafA, Pdx1 and NeuroD1
were ligated downstream of a c-myc tag. We constructed
a luciferase (Luc) reporter by ligation downstream of the
rat insulin 2 promoter (RIP) from  696 to +8 into
pGL3-basic (Promega) or pGluc-basic (New England
Biolabs) to generate RIP-Luc and RIP-Gluc constructs.
Serial deletions of RIP were generated by PCR and sub-
cloned into pGL3-basic. (Glis3RE)5-Luc was constructed
by ligation of ﬁve copies of complementary oligonucleo-
tides containing the Glis3RE sequence we identiﬁed in
this article. All expression constructs were conﬁrmed by
DNA sequencing.
Cellculture andtransfection
Rat 832/13 insulinoma cells (gift of Dr Christopher
Newgard, Duke University) were maintained as described
(24). We cultured NIH3T3 and BOSC23 cells (retrovirus
packaging cell line) in DMEM with 10% FBS. CHO
cells were cultured in Ham’s F12 supplemented with
10% FBS.
We used Lipofectamine 2000 (Invitrogen) for transfec-
tion according to the manufacturer’s instructions. Retro-
virally transduced cells (22) were selected in a medium
containing 1.0mg/ml puromycin and 200mg/ml hygromy-
cin B for 6–8 days.
For small interfering RNA (siRNA) experiments,
all control and Glis3 siRNAs were synthesized by
Dharmacon RNAi Technologies (Thermo Fisher Scienti-
ﬁc). The rat Glis3 targeting siRNA sequences were: sense,
50-GCAUCAGUGUACGAUUUUU-30; antisense, 50-AA
AUCGUACACUGUGAUGCUU-30. DharmaFECT
siRNA transfection reagents were used for delivering
siRNA into target cells. The control siRNA is a non-
targeting siRNA (Dharmacon RNAi Technologies,
D-001810-01-05).
RNA isolation and quantitative polymerase chain
reaction (qPCR)
Mouse tissues were dissected, snap frozen in liquid nitro-
gen and stored at  808C until use. We isolated pancreatic
islets from C57BL/6J mice as described previously (25).
We used TRIZOL (Invitrogen, Carlsbad, CA) for RNA
extraction and treated the RNA with ampliﬁcation grade
DNase I (Invitrogen) to remove genomic DNA contami-
nation. Reverse transcription was performed with
Superscript II reverse transcriptase kit (Invitrogen) using
oligo dT.
We performed qPCR using iQ SYBR Green Supermix
(Bio-Rad Laboratories, Hercules, CA) with ROX as the
reference dye. The housekeeping gene Cyclophilin A was
used as an internal control. Primer sequences are shown in
Supplementary Table S1. All primers span exons, except
MafA, which has only one exon. Ampliﬁcation was per-
formed using the Mx3000P Real-time PCR System
(Stratagene, La Jolla, CA) with the following parameters:
958C for 30s, 558C for 1min, 728C for 30s for 40 cycles.
The ﬁdelity of the PCR products was conﬁrmed by melt-
ing curve analysis and gel electrophoresis.
Luciferase assay
For transfection, we seeded cells in 24-well or 48-well cul-
ture plates and collected the cultured media (Gluc and
SEAP) or harvested the cells (Luc) 48h later using Lysis
Buﬀer (Promega Corporation, Madison, WI). Luc assays
were performed with the Dual-Luciferase Kit (Promega)
or Gaussia Luciferase Assay Kit (New England Biolabs).
The results were normalized to the activity of the internal
control BOS-Renilla Luc or SRa-SEAP Reporter mea-
sured with Phospha-Light
TM SEAP Reporter Gene
Assay System (Applied Biosystems).
Co-immunoprecipitation (Co-IP) assays
Nuclear protein extraction and Co-IP assays were per-
formed using a nuclear complex Co-IP kit (Active
Motif, Carlsbad, CA) as described by the manufacturer.
We incubated nuclear extract (300mg) with 3mgo f
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tgomery, TX), anti-Pdx1 antibody (gift of Dr Christopher
Wright, Vanderbilt University), anti-NeuroD1 antibody
(Santa Cruz Biotechnology, Inc.), or rabbit or goat IgG
as control in 500ml of low salt IP buﬀer overnight at 48C.
We added Protein-G or A sepharose beads (60ml, Sigma-
Aldrich) to the mixture and incubated for two additional
hours with rocking; we then washed the beads six times
with the low salt IP buﬀer. The immunoprecipitated pro-
teins were eluted in 40mlo f2   SDS sample buﬀer and
boiled for 10min, prior to analysis by western blotting.
Electrophoretic mobility shiftassay(EMSA)
We subcloned the Glis3 zinc ﬁnger domain (ZFD, 484–687
aa) into the pGBKT7 vector (Clontech Laboratories, Inc.)
and used the TNT Quick Coupled Transcription/
Translation Systems (Promega) according to the manufac-
turer’s instructions. This ZFD peptide was used for
EMSA using a Panomics ‘gel shift’ kit according to the
manufacturer’s instructions but with the addition of
100mM ZnCl2 to the binding buﬀer. Assays were con-
ducted using a biotin-labeled double-stranded oligonu-
cleotides probe containing the recognition sequence for
Glis3 (50-CTGAGACAATGTCCCCTGCTGTGAACTG
GTTCATC-30). Unlabeled wild-type or mutated Glis3REs
double stranded oligonucleotides were added as competi-
tors. Protein–DNA complexes were separated from free
probe by 6% non-denaturing polyacrylamide gel electro-
phoresis using Tris Borate buﬀer without EDTA.
Chromatin immunoprecipitation (ChIP)
We transfected 832/13 cells (1 10
8) with the c-myc-Glis3
plasmid and, after 48h, treated them with 1% formalde-
hyde for 10min at room temperature. Fixation was
stopped with the addition of glycine to a ﬁnal concentra-
tion of 0.125M and then the cells were treated with lysis
buﬀer (10mM EDTA, 1% SDS, 1mM PMSF, 1mg/ml
pepstatin, 1mg/ml leupeptin, 1mg/ml aprotinin, 50mM
Tris–HCL, pH 8.1) followed by three 10s pulses of soni-
cation (40W). We then incubated the sheared prepara-
tions with mouse monoclonal antibody against c-myc
overnight at 48C. Immune complexes were recovered
with protein sepharose A/G beads and cross-linking was
reversed by heating at 658C overnight. After removing the
protein by treatment with proteinase K, we ethanol pre-
cipitated the DNA and resuspended it in 50mlo fd H 2O for
PCR analysis. Primers spanning the Glis3RE fragment
were 50-AAGGACAAAGAAGGCCTCAC-30 and 50-TT
AGGGCTGGGGGTTACTGAATC-30. Primers used as
a negative control were 50-ACCCTGGTCACACAGTA
GGC-30 and 50-CCTGGTACTTTCTGGGGTC-30 which
span from  5400 to  5150 of the RIP 50 region.
Statistical analysis
The Student’s t-test was used for statistical analysis.
Results are presented as the mean   SD.
RESULTS
Production of mouse Glis3 and Glis3-NDH1 constructs
The mouse Glis3 gene (NM_175459) contains eleven
exons, which encode a 935 aa protein of 99.7kDa
(Figure 1A). We isolated a full-length cDNA clone of
Glis3 from mouse islet cDNAs. The cDNA encodes a
full-length Glis3 (7) protein that is 155 aa longer at
the amino-terminus than the previously reported Glis3
variants N155 (7) or Glis3-779 (3), resulting from con-
tributions from an alternate ﬁrst exon.
A cytidine insertion (insC) at the nucleotide 2067 of
the human GLIS3 cDNA underlies NDH1 syndrome
(8). We generated the homologous mouse 2067-insC
mutant, which we call mouse Glis3-NDH1, corresponding
to the NDH1 mutation found in human NDH1 syndrome
by PCR mutagenesis. The mouse Glis3-NDH1 encodes a
844 aa protein with a calculated MW of 89.8kDa
(Figure 1A).
Glis3 stimulates insulin gene transcription
In mice, we found the level of Glis3 transcripts to be high-
est in pancreatic islets, followed by kidney (Supplementary
Figure S1), in agreement with previous reports (7,8).
We examined the eﬀect of stable Glis3 overexpression on
insulin gene transcription in insulinoma 832/13 cells.
Retrovirally transduced Glis3 and Glis3-NDH1 constructs
were strongly expressed and achieved mRNA levels
6–12-fold higher than endogenous Glis3 by qPCR
(Figure 1B). Immunoblotting showed that both Glis3
constructs expressed proteins of the expected size in
832/13 cells (data not shown). By qPCR, the level of endo-
genous rat Ins1 transcript was unchanged but that of Ins2
transcript was increased by more than 10-fold by Glis3
overexpression compared to YFP-expressing control cells
(Figure 1C). Expression of Glis3-NDH1 did not aﬀect
Ins2 levels compared to the control YFP (Figure 1C), con-
sistent with the absence of a transactivating domain in
this truncated factor.
We then knocked down endogenous Glis3 expression
with siRNA in 832/13 cells, reducing Glis3 mRNA levels
by  60% (Figure 1D). Compared to control siRNA trea-
ted cells, the expression levels of both Ins1 and Ins2 were
signiﬁcantly decreased when Glis3 was knocked down
by siRNA (Figure 1E). A diﬀerent siRNA against Glis3
resulted in similar results (Supplementary Figure S2).
These results strongly suggest that Glis3 is involved in
the regulation of insulin gene transcription in b cells.
Glis3 stimulates insulin promoter activity
The DNA-binding and transcription activation domains
of Glis3 have been examined in non-insulin producing
cell lines by Beak et al. (7) and Kim et al. (3). Here, we
examined whether Glis3 and Glis3-NDH1 regulate insulin
gene promoter activity. Immunoblotting showed that
both constructs expressed proteins of the correct sizes in
CHO cells (Supplementary Figure S3A) and with similar
expression levels in 832/13 cells and NIH3T3 cells
(Supplementary Figure S3B). The transcription activation
mediated by the diﬀerent constructs was measured by
Nucleic Acids Research,2009, Vol.37, No. 8 2531co-transfection with the RIP-Gaussia luciferase (RIP-
Gluc) reporter into 832/13 cells and NIH3T3 cells. In
both cell types, Glis3 markedly enhanced RIP-Gluc
activity over background (BOS-c-myc). However, the
Glis3-NDH1 construct had no eﬀect (Figure 2A). In
832/13 cells, wild-type Glis3 stimulated RIP-Luc activity
in a dose-dependent manner (Figure 2B). Moreover, the
RIP-Gluc construct showed that c-myc-Glis3-NDH1
inhibited wild-type Glis3 activation of RIP-Gluc in a
dose-dependent manner both in a b cell line (832/13)
and in a non-b cell line (NIH3T3) (Figure 2C). We spec-
ulate that the mechanism of inhibition of RIP by
Glis3-NDH1 is due to competition for DNA binding
by the mutant, which lacks a transcription activation
domain.
Identification of DNA-binding sequence of Glis3
inthe insulin promoter
We mapped the region of RIP ( 696/+8) which interacts
with Glis3 by producing serial 50 deletion mutants of
RIP-Luc constructs. These were co-transfected with
c-myc-Glis3 into 832/13 cells. As shown in Figure 3A,
deletion of RIP sequences from  696 to  280 produced
no major eﬀects on promoter activity. However, further
deletion to  240 ( 240RIP) decreased Luc reporter activ-
ity by over 80% compared to  280RIP. Deleting
sequences from  280 to  255 had little additional eﬀect
(Figure 3B, ﬁrst two constructs), suggesting that the
critical region was between  255 and  241. To deﬁne
the cis-acting element further, we generated ﬁve mutant
constructs ( 255 M1 to M5, Figure 3B) within this
15-bp region, all of which ( 255M1-M5RIP) were
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Figure 2. Transcriptional activity of Glis3 and Glis3-NDH1. (A)Ab
cell line (832/13) and a non-b cell line (NIH3T3) were co-transfected
with RIP-Gluc, the internal control SRa-SEAP, and Glis3 or Glis3-
NDH1 expression constructs as indicated. Gaussia luciferase assay
was performed at 48h after transfection. The fold change of RIP pro-
moter activity caused by the c-myc-Glis3 constructs were compared to
that of the BOS vector expressing the c-myc tag alone. Results are
presented as mean   SD. (B) Dose-dependent induction of RIP-
mediated luciferase expression by Glis3. 832/13 cells were co-transfected
with RIP-Luc and BOS-c-myc together with increasing amounts of
c-myc-Glis3 as indicated. The amount of BOS-c-myc vector was
adjusted to maintain the same amount of total DNA in each well.
(C) Inhibition of Glis3-induced luciferase expression by the Glis3-
NDH1 mutant. 832/13 or NIH3T3 cells were co-transfected with
RIP-Gluc, c-myc-Glis3 and BOS-c-myc together with increasing
amounts of c-myc-Glis3-NDH1 as indicated.
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Figure 1. Glis3 stimulates insulin gene transcription. (A) Schematic rep-
resentation of the mouse Glis3 and Glis3-NDH1 constructs. (B, C) 832/
13 cells were stably infected with mouse Glis3 and Glis3-NDH1 con-
structs or a YFP control retroviral construct. Mouse/rat Glis3 (B) and
rat Ins1 and Ins2 (C) mRNA levels were quantiﬁed by qPCR relative to
cyclophilin A. The Glis3 and Glis3-NDH1 values are shown relative to
YFP-expressing cells and are expressed as the mean   SD. (D, E) 832/
13 cells were transiently transfected with siRNA against rat Glis3 or a
control siRNA. Glis3 (D) and rat Ins1 and Ins2 (E) mRNA levels were
quantiﬁed by qPCR relative to cyclophilin A. The relative Glis3, Ins1
and Ins2 expression levels in Glis3 siRNA transfected cells were com-
pared to those in control siRNA-treated cells and presented as the
mean   SD. Each experiment was performed in triplicate and repeated
three times.  P<0.05;    P<0.001.
2532 Nucleic Acids Research, 2009, Vol. 37,No. 8associated with a marked reduction in reporter activity,
compared to the  255RIP wild-type construct, suggesting
that this entire region was required for Glis3 binding
(Figure 3B). Sequence alignment of insulin promoters
from mouse, rat and human indicates that this region
is highly conserved (Figure 3C), consistent with an
important role as the Glis3 response element (Glis3RE).
We then ligated ﬁve copies of the rat or human Glis3RE
sequence to the RIP TATA box [(Glis3RE)5-Luc] and
found that both rat and human Glis3RE constructs were
activated by c-myc-Glis3, but not c-myc-Glis3-NDH1
(Figure 3D). These results demonstrate that the 15-bp
region G(T/C)CCCC(T/A)GCTGTGA(A/G) in the rat
ins2 and human insulin promoters functionally interacts
with Glis3 and is crucial to promoter activity.
Glis3 binds to theGlis3 responseelement
To conﬁrm the physical interaction of Glis3 with the
putative rat Glis3RE sequence (GTCCCCTGCTGT
GAA), we performed EMSA using the ZF domain Glis3
(ZFD). A biotinylated double-stranded oligonucleotide
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Figure 3. Identiﬁcation of Glis3 DNA-binding sequence in RIP region. (A) The rat insulin 50 ﬂanking serial deletion constructs (0.2mg) were
co-transfected with BOS-c-myc (0.2mg) or c-myc-Glis3 (0.2mg). The activity of each construct is expressed relative to the background activity of
BOS-c-myc (equal to 1.0). (B) The sequences and activities of the wild-type and mutation constructs (M1–M5) between  255 and  241 of RIP are
shown. The mutated nucleotides are underlined. 832/13 cells were co-transfected with c-myc-Glis3 (0.2mg) and the various RIP mutant constructs
(0.2mg) as indicated. Dual-luciferase assays were performed at 48h after transfection. The activity of each construct was normalized to that induced
by the co-transfection of BOS-c-myc and  280 RIP-Luc. (C) Alignment of the 15-bp sequences (Glis3RE) located between  255 and  241 of the rat
Ins2 promoter compared to mouse and human. (D) Schematic view of ﬁve tandem copies of the Glis3RE fused upstream of the RIP
TATA box to drive expression of luciferase [(Glis3RE)5-Luc]. 832/13 cells were co-transfected with the rat or human (Glis3RE)5-Luc with
c-myc-Glis3 or c-myc-Glis3-NDH1 constructs. The activity of each construct was normalized to that obtained with BOS-c-myc. Each experiment
was performed in triplicate and repeated three times. Minor variation between experiments in the basal expression with deletion of sequences between
 280 and  240, with a decrease of 42.5% in (A) and 32% in (B).
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probe. We found that Glis3 (ZFD) bound to the Glis3RE
( 265 to  230) probe and the complex was abolished by a
2-fold molar excess of unlabeled Glis3RE oligonucleotide,
whereas 2-fold molar excess of all ﬁve mutant Glis3REs
corresponding to  255M1 to M5 failed to signiﬁcantly
compete for binding (Figure 4A). In the presence of
20-fold molar excess competitors, M1, M2 and M4 still
failed to compete for the binding of Glis3 (ZFD) to wild-
type Glis3RE, while M3 and M5 partially competed for the
binding (Figure 4A, bottom). Therefore, there is substan-
tial speciﬁcity in the binding of Glis3 (ZFD) binds to
Glis3RE in vitro.
To determine if Glis3 also is bound to the endogenous
RIP Glis3RE in the cell, we performed a ChIP assay.
832/13 cells were transfected with c-myc-Glis3 and, 48h
later, c-myc antibody was used to immunoprecipitate the
c-myc-Glis3–DNA complexes. Primers corresponding to
the RIP fragment spanning  280 to +8 were used for
PCR ampliﬁcation. As shown in Figure 4B, the c-myc
antibody was able to immunoprecipitate the RIP region,
conﬁrming that Glis3 was bound to the promoter in situ.
There was no ampliﬁcation of DNA for the controls
which included absence of DNA template, absence of
antibody, use of mouse IgG, or use of c-myc Ab without
c-myc-Glis3 transfection. These controls conﬁrmed the
speciﬁcity of the c-myc-Glis3–DNA interaction. As an
additional control, a remote region of the RIP promoter
( 5400 to  5150) also was not ampliﬁed in the experi-
ment. These results show that Glis3 is capable of binding
to the endogenous RIP promoter in 832/13 cells, directly
regulating insulin gene transcription.
Glis3 synergistically stimulates insulin transcription
activity withPdx1, MafAand NeuroD1
Pdx1, MafA and NeuroD1 are major transcription factors
which mediate insulin gene transcription in the b cell and
are required for b cell maintenance (12–14). Therefore, we
examined the functional interaction of Glis3 with these
known insulin gene transactivators. We co-transfected
constructs expressing c-myc-Pdx1, c-myc-MafA and
c-myc-NeuroD1 with RIP-Gluc into NIH3T3 cells with
or without c-myc-Glis3. 832/13 cells were not used for
this experiment because we wanted to avoid contribu-
tions by the endogenous RIP transactivators. Immuno-
blotting showed that c-myc-Pdx1, c-myc-MafA and
c-myc-NeuroD1 constructs express proteins with correct
sizes (Supplementary Figure S2A). RIP-Gluc activity was
signiﬁcantly induced by Glis3, MafA and Pdx1 individ-
ually, but not by NeuroD1 (Figure 5A). Co-transfection
of c-myc-Glis3 with c-myc-tagged Pdx1, MafA and
NeuroD1, revealed a synergistic interaction between
Glis3 and all of these factors. These results suggest that
Glis3 functionally interacts with other insulin gene trans-
activators to enhance insulin gene transcription.
Glis3 binds to Pdx1,MafA and NeuroD1 in 832/13cells
Because of the functional interaction of Glis3 with
b-cell-speciﬁc transcription factors, we examined if
Glis3 also physically interacts with them. We expressed
c-myc-Glis3 with c-myc-Pdx1, MafA or NeuroD1 in
832/13 cells, and used antibodies to Pdx1, MafA and
NeuroD1 to immunoprecipitate the complexes from the
nuclear extract. Anti-c-myc antibody was used in western
blot analysis to detect Glis3 that had co-precipitated
with Pdx1, MafA and NeuroD1 (Figure 5B). The MafA,
Pdx1 and NeuroD1 complexes are speciﬁc, because
pre-immune rabbit or goat IgG did not immunoprecipi-
tate the c-myc-Glis3 protein. We also performed the
co-immunoprecipitation experiments in 832/13 cells over-
expressing c-myc-Glis3 but without expression of the
other factors, in order to examine interactions with endo-
genous Pdx1, MafA and NeuroD1. Western blot analysis
of the immunoprecipitated complexes showed that Glis3
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Figure 4. Glis3 binds to the RIP Glis3 response element (Glis3RE). (A)
Synthetic biotinylated RIP sequence from  265 to  230, containing
Glis3RE, was used as a probe in EMSA with an in vitro translated
Glis3 ZFdomain [Glis3 (ZFD)] peptide. The speciﬁcity of the protein–
DNA complex (lane 2) was conﬁrmed by competition with a 2-fold
molar excess of unlabeled wild-type competitor (lanes 3) but not a
2-fold molar excess of the mutants M1 to M5 (lanes 4–8). The mobility
shift bands with asterisk showed the results of similar experiment using
20-fold molar excess wild-type or ﬁve mutant competitors. The speciﬁc
bands are indicated by arrows. (B) The c-myc-Glis3–DNA complex was
immunoprecipitated by c-myc antibody from 832/13 cells which had
been transfected with c-myc-Glis3. Immunoprecipitated DNA was pur-
iﬁed and analyzed by PCR using primers speciﬁcally spanning the
Glis3RE region (RIP  280 to +8) or region remote from Glis3RE
( 5400 to  5150). Lane 1, total input DNA (1:100 dilution); lane 2,
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c-myc-Glis3 transfection; lane 4, no DNA template; lane 5, immuno-
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of antibody.
2534 Nucleic Acids Research, 2009, Vol. 37,No. 8co-precipitated with endogenous Pdx1, MafA, but not
NeuroD1 in this case (Supplementary Figure S4). A
possible reason for the latter result is that the mouse
NeuroD1 antibody could not recognize endogenous rat
NeuroD1 protein eﬀectively for immunoprecipitation.
Alternatively, the endogenous NeuroD1 may be at a
level that is too low for detection.
Glis3 regulates the expression of bcell enriched
transcription factors
We have shown that Glis3 regulates insulin gene transcrip-
tion by direct binding to the insulin promoter and also
by interacting with insulin gene transcription factors,
Pdx1, MafA and NeuroD1. We next examined if Glis3
aﬀected the expression of key b-cell-speciﬁc transcription
factors. Quantitative PCR showed that the mRNA expres-
sion of MafA was signiﬁcantly upregulated while Nkx6-1
and Pax6 were signiﬁcantly downregulated in Glis3 stably
overexpressing cells as compared to YFP-expressing
control cells (Figure 6A); Glis3-NDH1 had no eﬀect on
the expression of these genes (Figure 6A). The transcript
levels of Pdx1, NeuroD1 and Pax4 were not aﬀected by
Glis3 overexpression (Figure 6A). When we knocked
down the endogenous Glis3 expression with siRNA in
832/13 cells, MafA expression was signiﬁcantly decreased
whereas Nkx6-1 and Pax6 message levels were signiﬁ-
cantly increased (Figure 6B), results that were congruent
with those of Glis3 overexpression. Because all of these
factors directly regulate insulin gene expression (19,20),
it appears that Glis3 also has an indirect role in the reg-
ulation of the insulin promoter through its eﬀects on
the mRNA levels, and possibly protein levels, of these
b-cell-speciﬁc factors.
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Figure 5. Glis3 synergistically induces RIP-driven transcriptional
activity with Pdx1, MafA and NeuroD1. (A) NIH3T3 cells were
co-transfected with RIP-Gluc and c-myc-Glis3, c-myc-MafA, c-myc-
Pdx1 and c-myc-NeuroD1 individually or in combination with c-myc-
Glis3 as labeled. The relative luciferase activity is presented compared
to that of Bos-c-myc with pGluc-basic (equal to 1.0). The background
luciferase activity of pGluc-basic also is shown. (B) 832/13 cells were
transfected with c-myc-Glis3 and c-myc-Pdx1, c-myc-MafA or
c-myc-NeuroD1. Forty-eight hours after transfection, nuclear proteins
were isolated and immunoprecipitated either with a rabbit anti-mouse
MafA, goat anti-mouse Pdx1 or goat anti-mouse NeuroD1 antibody or
appropriate control IgGs. The immunoprecipitates were analyzed with
western blotting using anti-c-myc antibody. g: goat; r: rabbit.
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Figure 6. Glis3 regulates islet-enriched transcription factors expression.
(A) 832/13 cells were stably infected with Glis3, Glis3-NDH1 or the
control YFP retroviral constructs, and MafA, Pdx1, NeuroD1, Nkx6-1,
Pax6 and Pax4 mRNA levels were analyzed by qPCR relative to cyclo-
philin A. The expression values were normalized to those for YFP
infected cells and presented as mean   SD. (B) 832/13 cells were tran-
siently transfected with siRNA against rat Glis3 or control siRNA.
MafA, Pdx1, NeuroD1, Nkx6-1, Pax6 and Pax4 mRNA expression
were analyzed by qPCR. The expression values were normalized to
those for control siRNA treated cells and presented as mean   SD.
 P<0.05;   P<0.01;    P<0.001.
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Glis3 is a member of Kru ¨ ppel-like ZF proteins and has
the potential to function as a transcription activator or
repressor (3). It is highly expressed in human pancreatic
b cells (8) and mouse islets and rat insulinoma 832/13 cells.
The recent discovery that mutations in the GLIS3 gene are
responsible for neonatal diabetes and congenital hypo-
thyroidism (NDH) in humans (8) motivated us to focus
on the function of this factor in b cells.
In this study, we showed that Glis3 overexpression in
rat 832/13 insulinoma cells markedly upregulated Ins2
gene expression. However, both Ins1 and Ins2 were down-
regulated when endogenous Glis3 was knocked down by
siRNA, suggesting that it is involved directly or indirectly
in the regulation of both genes. Our data demonstrated
that Glis3 is able to directly bind the Glis3RE sequence of
the rat Ins2 promoter using ChIP and EMSA, so it likely
has a direct eﬀect. The lack of response of Ins1 to Glis3
overexpression may indicate that its expression levels
are already near or at maximum in 832/13 cells and an
increase in Glis3 levels cannot further enhance Ins1
expression. A similar phenomenon was noted previously
for the lack of activation of mouse Ins1, Ins2 and Pdx1
expression by MafB overexpression in bTC3 cells even
though it binds to the promoters (26,27). We cannot
identify a Glis3RE sequence in the rat Ins1 promoter
region. However, Glis3 can increase MafA mRNA expres-
sion and as it is known that MafA is capable of activating
Ins1 promoter, we speculate that, although the Ins1 pro-
moter is not directly bound by Glis3, Glis3 has eﬀects
on other b cell transcription factors which may in turn
inﬂuence Ins1 expression.
We also showed that Glis3 expression stimulated the
rat insulin 2 promoter (RIP-Gluc) in both NIH3T3 cells
and 832/13 cells and mapped the regulatory region
required for Glis3 activation to a 15-bp sequence ( 255
to  241) of the promoter. The site GTCCCCTGCTGTG
AA shares 100% homology with a similar region of the
mouse Ins2 promoter, and is 80% conserved with a
sequence from the human insulin promoter. We showed
that Glis3 binds to this sequence and can activate the
transcription of both human and rodent (Glis3RE)5-
TATA box constructs, conﬁrming its place as a bona ﬁde
Glis3 binding and transcription activation site. By ChIP
analysis, we conﬁrmed that Glis3 was able to bind to
the region of interest in the endogenous Ins2 promoter
in 832/13 cells as well.
The sequence we identiﬁed diﬀers from the 11bp con-
sensus identiﬁed by Beak et al. (7) (G/C)TGGGGGGGT
(A/C) using PCR ampliﬁcation of random oligonucleotide
sequences. Their consensus binds to Glis3 with high aﬃn-
ity and can mediate transcription activation in vitro (7).
However, it is an artiﬁcial binding sequence that has
not been identiﬁed as of yet in any 50 regulatory regions.
A computer search also failed to ﬁnd any matching
homologous sequences in the rat Ins2 promoter ( 696/
+8). The FGF18 promoter contains a Glis3-binding site
with the sequence AACCCCCAAA (6). We found a
similar sequence AACCCCCAG at  7 to +1 of RIP.
However, deletion analysis showed that the proximal
promoter region ( 75/+1) of RIP is minimally activated
by co-transfected Glis3 and this sequence overlaps the
transcription initiation site +1, making it unlikely that
this region is involved in Glis3-activated gene transcrip-
tion. The Glis3RE ( 269 to  255) identiﬁed in this paper
partially overlaps with a previously characterized element
(GAGACATTTGCCCCCAGCTGT) known as a nega-
tive regulatory element (NRE,  279 to  258) (28,29)
that lies within the glucose sensing Z element ( 292 to
 243) of the human insulin promoter (30,31).
The human NDH1 mutation of GLIS3 contains a single
base insertion at nucleotide 2067. It encodes a mutant
protein that is truncated at its C-terminus at aa 844 due
to a translation frameshift (8). The mechanism by which
this mutation causes NDH has not been elucidated. Our
analysis shows that the analogous mutation of the mouse
Glis3 abrogates the transcription activity of the factor,
consistent with localization of the activation domain at
the C-terminus (7). Furthermore, Glis3-NDH1 acts as a
dominant negative factor when expressed together with
wild-type Glis3 in insulinoma cells and NIH3T3 cells.
The putative mechanism is that Glis3-NDH1 binds to
DNA and competes with the wild-type Glis3, but cannot
activate transcription. We speculate that the NDH1
mutant protein might profoundly aﬀect wild-type Glis3
function during early pancreas development.
In addition to direct eﬀects on insulin promoter activity,
we showed that Glis3 is capable of interacting with other
key b-cell-speciﬁc transcription factors. MafA is a crucial
factor for the assembly and function of the insulin gene
transcription complex. Previous studies have shown that
Pdx1, MafA and NeuroD1 synergistically activate the
insulin promoter (12–14). Our present results show that
Glis3 physically interacts with Pdx1, MafA and NeuroD1
in co-precipitation experiments. In addition, Glis3
shows cooperative interactions with Pdx1, MafA and
NeuroD1 for insulin promoter activation. These results
lead us to conclude that Glis3 modulates insulin gene
expression, both directly through binding to the insulin
promoter and indirectly by modulating the activity of
other b-cell-enriched transcription factors.
Manipulation of Glis3 levels through stable overexpres-
sion or siRNA knock-down also aﬀected the levels of
several other Glis3 target genes in b cells, including
MafA, Nkx6-1 and Pax6. Therefore, Glis3 also may mod-
ulate insulin gene transcription indirectly through changes
in the levels of these factors. The mRNA expression of
MafA was upregulated in Glis3-overexpressing cells, and
downregulated in Glis3-knockdown cells, suggesting that
MafA could be a Glis3 target gene. Nkx6-1 is initially
expressed broadly in the developing pancreatic bud, but
eventually is restricted exclusively to b cells (32). It has
been shown that Nkx6-1 can repress insulin promoter
activity in b cells (33). Nkx6-1 mRNA expression was
signiﬁcantly downregulated by Glis3 overexpression, and
upregulated in cells treated with Glis3 siRNA. Thus,
Nkx6-1 could be another mediator of Glis3 action
in b cells. Pax6 works through the C2 element of the
rat Ins1 promoter (16). Similar to Nkx6-1, Pax6
was decreased in Glis3-overexpressing b cells and
increased in Glis3-knockdown cells. We only ﬁnd that
2536 Nucleic Acids Research, 2009, Vol. 37,No. 8Glis3-NDH1 inhibits wild-type Glis3 when co-expressed
during transient transfection. We do not see Glis3-
NDH1 inhibition of MafA expression or stimulation of
expression of Nkx6-1 and Pax-6 when overexpressed in
832/13 cells. Whether authentic Glis3RE sequences are
present in the 50 regulatory regions of the genes for the
aﬀected factors and will require further investigation.
In conclusion, we have demonstrated for the ﬁrst
time that Glis3 regulates insulin gene transcription in
a cell line derived from b cells. Furthermore, we have
identiﬁed a 15-bp sequence of the Ins2 promoter
required for Glis3 binding, and this sequence is highly
conserved among mouse, rat and human, underscoring
its role in insulin gene regulation. Our data indicate
that Glis3 can act in concert with other known insulin
gene transactivators, such as Pdx1, MafA and NeuroD1.
Finally, Glis3 expression also may modulate insulin
gene transcription by eﬀects on the levels of other
b-cell-enriched transcription factors such as MafA,
Nkx6-1 and Pax6.
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